People with allergic reaction to mRNA vaccines can get 2nd dose; Popular antacids not linked to severe COVID-19 outcomes

The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19.

Most with allergy to first mRNA shot can get second dose

Most people with allergic reactions to the first dose of an mRNA COVID-19 vaccine from either Pfizer/BioNTech or Moderna can safely receive the second dose, a new study shows.

The rates of allergic reactions to these vaccines have been reported to be as high as 2%, with anaphylaxis, the most serious kind, occurring in up to 2.5 of every 10,000 vaccine recipients, the researchers said.

They reviewed data on 189 adults with first-dose reactions to one of these vaccines, such as flushing, dizziness or lightheadedness, tingling, throat tightness, hives, and wheezing or shortness of breath.

Most of these adults - 84% - received the second dose of the vaccine, with about a third taking an antihistamine beforehand.

All of them tolerated the second dose, including those with first-dose anaphylactic reactions.

Any potentially allergic symptoms that developed after the second dose were mild and easily controlled, the researchers reported on Monday in JAMA Internal Medicine.

"Complete two-dose vaccination has become even more important with the Delta variant and we suspect there are many more people who did not get their second shot because of allergic symptoms," said coauthor Dr. Matthew Krantz from Vanderbilt University.

"Our data suggest that most patients with immediate and potentially allergic reactions to mRNA COVID-19 vaccines tolerate a second dose," his team concluded.

Popular antacids not linked to severe COVID-19 outcomes

Widely-used antacid medications known as proton pump inhibitors (PPIs) are not linked with severe COVID-19 outcomes, a new study found.

Researchers with the US Veterans Affairs Health Care System analyzed data on nearly 15,000 veterans with positive COVID-19 tests, about 42% of whom were using PPIs such as Procter & Gamble's Prilosec (omeprazole), Takeda Pharmaceuticals' Prevacid (lansoprazole), and AstraZeneca's Nexium (esomeprazole).

After taking patients' underlying COVID-19 risk factors into account, the risk of becoming sick enough to need mechanical ventilation or to die within two months of diagnosis was no different between regular PPI users and non-users, the researchers reported on Sunday on medRxiv ahead of peer review.

"With respect to COVID-19," the researchers concluded, "patients and providers should feel safe to continue to use PPIs at the lowest effective dose for approved indications." -- Reuters